DK0918795T3 - Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati - Google Patents
Antiangiogene lægemidler til behandling af cancer, arthritis og retinopatiInfo
- Publication number
- DK0918795T3 DK0918795T3 DK98911778T DK98911778T DK0918795T3 DK 0918795 T3 DK0918795 T3 DK 0918795T3 DK 98911778 T DK98911778 T DK 98911778T DK 98911778 T DK98911778 T DK 98911778T DK 0918795 T3 DK0918795 T3 DK 0918795T3
- Authority
- DK
- Denmark
- Prior art keywords
- arg
- ile
- gly
- thr
- val
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 206010003246 arthritis Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 208000017442 Retinal disease Diseases 0.000 title 1
- 206010038923 Retinopathy Diseases 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 3
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 150000008574 D-amino acids Chemical group 0.000 abstract 1
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82066797A | 1997-03-17 | 1997-03-17 | |
| PCT/US1998/005327 WO1998041542A1 (en) | 1997-03-17 | 1998-03-16 | Antiangiogenic drug to treat cancer, arthritis and retinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0918795T3 true DK0918795T3 (da) | 2005-03-14 |
Family
ID=25231427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98911778T DK0918795T3 (da) | 1997-03-17 | 1998-03-16 | Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0918795B1 (de) |
| JP (2) | JP4254972B2 (de) |
| AT (1) | ATE280781T1 (de) |
| CA (1) | CA2255661C (de) |
| DE (1) | DE69827223T2 (de) |
| DK (1) | DK0918795T3 (de) |
| ES (1) | ES2231973T3 (de) |
| PT (1) | PT918795E (de) |
| WO (1) | WO1998041542A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716963B1 (en) | 1998-05-22 | 2004-04-06 | Abbott Laboratories | Peptide antiangiogenic drugs |
| US6774211B1 (en) | 1998-05-22 | 2004-08-10 | Abbott Laboratories | Peptide antiangiogenic drugs |
| AU764277B2 (en) * | 1998-05-22 | 2003-08-14 | Abbvie Inc. | Peptide antiangiogenic drugs |
| DK1232183T3 (da) * | 1999-11-22 | 2006-05-29 | Abbott Lab | Peptider, som har antiangiogen aktivitet |
| US6777535B1 (en) | 1999-11-22 | 2004-08-17 | Abbott Laboratories | N-alkylated peptides having antiangiogenic activity |
| CO5261544A1 (es) * | 1999-11-22 | 2003-03-31 | Abbott Lab | Peptidos n-alquilados que tienen actividad antiangiogenica |
| US6753408B1 (en) | 1999-11-22 | 2004-06-22 | Fortuna Haviv | Peptides having antiangiogenic activity |
| US20020183242A1 (en) * | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
| US20030119746A1 (en) * | 2001-10-31 | 2003-06-26 | Fortuna Haviv | Hepta-and octapeptides having antiangiogenic activity |
| CN1314705C (zh) * | 2005-06-03 | 2007-05-09 | 中国药科大学 | 高效抑制血管生成多肽及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5200397A (en) * | 1990-02-22 | 1993-04-06 | W. R. Grace & Co.-Conn. | Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity |
| WO1993016716A1 (en) * | 1992-02-24 | 1993-09-02 | Northwestern University | Method and composition for inhibiting angiogenesis |
| JPH09505555A (ja) * | 1993-08-13 | 1997-06-03 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ＴＧＦ−βの活性を刺激および阻害する方法および組成物 |
-
1998
- 1998-03-16 PT PT98911778T patent/PT918795E/pt unknown
- 1998-03-16 JP JP54076598A patent/JP4254972B2/ja not_active Expired - Lifetime
- 1998-03-16 DK DK98911778T patent/DK0918795T3/da active
- 1998-03-16 DE DE69827223T patent/DE69827223T2/de not_active Expired - Lifetime
- 1998-03-16 EP EP98911778A patent/EP0918795B1/de not_active Expired - Lifetime
- 1998-03-16 WO PCT/US1998/005327 patent/WO1998041542A1/en active IP Right Grant
- 1998-03-16 CA CA002255661A patent/CA2255661C/en not_active Expired - Lifetime
- 1998-03-16 ES ES98911778T patent/ES2231973T3/es not_active Expired - Lifetime
- 1998-03-16 AT AT98911778T patent/ATE280781T1/de active
-
2008
- 2008-06-24 JP JP2008164055A patent/JP2009001576A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0918795A1 (de) | 1999-06-02 |
| JP2001506671A (ja) | 2001-05-22 |
| DE69827223T2 (de) | 2006-02-02 |
| WO1998041542A1 (en) | 1998-09-24 |
| PT918795E (pt) | 2005-02-28 |
| CA2255661C (en) | 2004-08-10 |
| ATE280781T1 (de) | 2004-11-15 |
| JP4254972B2 (ja) | 2009-04-15 |
| CA2255661A1 (en) | 1998-09-24 |
| EP0918795B1 (de) | 2004-10-27 |
| JP2009001576A (ja) | 2009-01-08 |
| ES2231973T3 (es) | 2005-05-16 |
| DE69827223D1 (de) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5229489A (en) | Parathyroid hormone antagonists | |
| AR036196A1 (es) | Agentes de contraste multimericos dirigidos a base de peptidos | |
| GB9720054D0 (en) | Biological products | |
| EP0254080A3 (en) | Malonic acid derivatives and methods for their synthesis | |
| DE69942035D1 (de) | Menschliches parathyroidhormon, modifikationen, herstellung und verwendung | |
| RU94036773A (ru) | Домен i ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена i | |
| CZ20022740A3 (cs) | Sloučenina, způsob přípravy sloučeniny, farmaceutický prostředek a způsob léčení rakoviny | |
| DK0918795T3 (da) | Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati | |
| EP0597997B1 (de) | Peptide mit einer lanthionin-brücke | |
| AU5963290A (en) | Inhibition of the n-end rule pathway in living cells | |
| DE69530404D1 (de) | Analogen des keratinozytenwachstumfaktors | |
| AU5362190A (en) | Novel peptides, and antidementia agents containing the same | |
| DE69722618D1 (en) | Peptide | |
| DE69836428D1 (de) | Karzinostatische wirkstoffe | |
| Schmittberger et al. | Synthesis of the palmitoylated and prenylated C-terminal lipopeptides of the human R-and N-Ras proteins | |
| CA2181590A1 (en) | Peptomers with enhanced immunogenicity | |
| Ding et al. | Structure–activity relationships of side-chain modified didemnins | |
| US6268339B1 (en) | Lanthionine bridged peptides | |
| WO1997010262A1 (fr) | Derives peptidiques | |
| Boyer et al. | Critical role of an amino acid residue in a T cell determinant is due to its interaction with a neighboring non‐critical residue | |
| KR950011466A (ko) | 선형 결합 억제제 | |
| NZ508812A (en) | Peptides for the prevention or treatment of HIV | |
| Spatola | Synthesis of pseudopeptides | |
| Borsuk et al. | Application of substituted 2-(trimethylsilyl) ethyl esters to suppress diketopiperazine formation | |
| DE3882233D1 (de) | Gefaessaktive peptide. |